Top 5 issues to look out for in the access to medicines debate in Europe

For pharmaceuticals in Europe, 2016 marked a turning point. For the first time, in a frank and comprehensive dialogue, all the problems and deficiencies of the current business model were finally brought centre stage and discussed at the highest political level. Tough questions were asked and manufacturers were forced to provide some real answers. So [read more…]

Priority Medicines (PRIME)

PRIME is a scheme launched by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients [read more…]

The European Medicines Regulatory Framework

  The European regulatory system for medicines is a unique model in the global regulatory environment. The system is based on a network of all national medicines regulatory authorities for both human and veterinary medicines from Member States in the European Union and European Economic Area, united in the Heads of Medicines Agencies (HMA), and [read more…]